Pharma’s Diabetes War Escalates

By Dave Williamson Today Fool.com health-care analysts David Williamson and Max Macaluso look at one of the largest and most profitable segments of the pharmaceutical space: diabetes ...

Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical Development Of GSK2251052

PALO ALTO, CALIF.–(BUSINESS WIRE)– Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its collaboration partner GlaxoSmithKline (GSK) has discontinued clinical development ...

New Diabetes Drug Can Bolster J&J’s $74 Value

By Trefis Team Johnson & Johnson’s (NYSE:JNJ) experimental drug, canagliflozin, for type 2 diabetes has shown efficacy in phase III trials in reducing blood sugar in diabetics ...

Pfizer to challenge Indian ruling overturning cancer drug patent

NEW DELHI: US drug giant PfizerBSE 0.85 % said Friday it will appeal against an Indian ruling overturning a patent for a cancer drug, saying the decision raises questions about intellectual ...

Fosun set to tap HK stock market for US$600m

After shelving its plan because of weak market sentiment, the Shanghai company is now ready to sell shares in its pharmaceutical offshoot Ray Chan ray.utchan@scmp.com Shanghai Fosun ...

Healthcare Business Review: Watson Gets EU Approval, Stryker’s Bad News

By Mark Lawson Watson Pharmaceuticals (NYSE:WPI) sees its proposed purchase of the Swiss-based pharmaceutical company Actavis okayed by the European Commission, which commented in ...

Will The Sanofi Pompe Paradigm Play Out With Neuralstem And Lou Gehrig’s Disease?

All too often I see fights over microcap development stage companies on UGC financial sites that do nothing more than amuse me. Accusations of agendas are thrown, predictions are made, ...

Insider Sales Case Study: It Is A Deceptive Indicator Of Insider Confidence In A Company

Insider transactions are good indicators of a company’s health and prospects. Now, of course, insider transactions are mainly of two sorts – buy and sell. While buying strongly ...

Takeda to buy LigoCyte, signs pact with India’s Advinus

KEVIN GROGAN Takeda is paying $60 million upfront to acquire the USA’s LigoCyte Pharmaceuticals and expand its vaccines business. The Japan-based major will pay more depending ...

Novo to Hire 1,000 People in 2 Years in Emerging Markets

By Albertina Torsoli Novo Nordisk A/S (NOVOB), the world’s biggest insulin maker, plans to hire about 1,000 people in the next two years to expand treatment for diabetes in emerging ...

NICE reverses position on new use for Novartis’ Lucentis

Discount does the trick in new move in eye drug competition By Eric Palmer The U.K.’s drug price watchdog apparently achieved the effect it intended when it earlier turned its ...

Acadia Pharmaceuticals – Breaking Out For A Second Leg Up

This article was written by Rajesh Patel, Ph.D. Acadia Pharmaceuticals (ACAD) has been running up ahead of anticipated clinical trial results to be released next month. After a recent ...
Page 93 of 93« First...102030...8990919293
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS